Brazil has agreed not to break the patent on a key HIV/Aids drug after a commitment by its US manufacturer to reduce the drug's price.
Abbott Laboratories has agreed to reduce the price of the drug over the next six years after 10 days of talks with the Brazilian government.
Brazil had said it would start making a cheaper generic version of the drug, Kaletra, unless Abbott Laboratories cut its price.
Kaletra is one of the most widely used anti-retroviral drugs, which are essential to the treatment of HIV.
Brazil currently pays Abbott $107 million a year for the drug, which is provided to patients for free.
The new deal will save the government more than $250 million over the next six years and enable them to treat more patients suffering from HIV/Aids.
